Spots Global Cancer Trial Database for fgfr2 gene mutation

Every month we try and update this database with for fgfr2 gene mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib	NCT05052372	Bladder Cancer Urothelial Carc... Transitional Ce... Platinum-Resist... Bladder Urothel... FGFR Mutation FGFR2 Gene Muta... FGFR3 Gene Muta... FGFR2 Amplifica... Locally Advance... Metastatic Urot... Refractory Blad... Refractory Blad...	Balversa	18 Years -	xCures
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma	NCT04919642	Cholangiocarcin... FGFR2 Fusion FGFR2 Gene Muta... FGFR1 Alteratio... FGFR3 Alteratio...	TT-00420	18 Years -	TransThera Sciences (Nanjing), Inc.
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma	NCT02150967	Advanced Cholan... FGFR2 Gene Muta...	BGJ398 (infigra...	18 Years -	QED Therapeutics, Inc.
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma	NCT02150967	Advanced Cholan... FGFR2 Gene Muta...	BGJ398 (infigra...	18 Years -	QED Therapeutics, Inc.
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements	NCT05565794	Intrahepatic Ch... FGFR2 Gene Muta... FGFR2 Gene Rear... FGFR2 Gene Tran...	Pemigatinib	18 Years -	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib	NCT05052372	Bladder Cancer Urothelial Carc... Transitional Ce... Platinum-Resist... Bladder Urothel... FGFR Mutation FGFR2 Gene Muta... FGFR3 Gene Muta... FGFR2 Amplifica... Locally Advance... Metastatic Urot... Refractory Blad... Refractory Blad...	Balversa	18 Years -	xCures
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer	NCT02706691	FGFR Gene Ampli... FGFR1 Gene Ampl... FGFR2 Gene Ampl... FGFR2 Gene Muta... FGFR3 Gene Muta... Head and Neck S... Human Papilloma... Recurrent Head ... Recurrent Nasop... Recurrent Oroph...	BGJ398	18 Years -	University of Chicago
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer	NCT02965378	FGFR1 Gene Ampl... FGFR1 Gene Muta... FGFR2 Gene Ampl... FGFR2 Gene Muta... FGFR3 Gene Ampl... FGFR3 Gene Muta... Recurrent Squam... Stage IV Squamo...	Docetaxel FGFR Inhibitor ... Laboratory Biom...	25 Years -	SWOG Cancer Research Network
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma	NCT02150967	Advanced Cholan... FGFR2 Gene Muta...	BGJ398 (infigra...	18 Years -	QED Therapeutics, Inc.
Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations	NCT04096417	FGFR1 Gene Ampl... FGFR1 Gene Muta... FGFR1 Gene Tran... FGFR2 Gene Ampl... FGFR2 Gene Muta... FGFR2 Gene Tran... FGFR3 Gene Ampl... FGFR3 Gene Muta... FGFR3 Gene Tran... Metastatic Colo... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co...	Pemigatinib Quality-of-Life...	18 Years -	Academic and Community Cancer Research United

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: